As we mentioned on the Women Want Strong Men podcast, medications like Semaglutide and Tirzepatide typically make patients more in tune with their bodys signals
Initial phase: Typically, during the initial phase, lipotropic injections may be administered more frequently, such as once or twice per week, for a few weeks
The difference between having amazing results and frustrating plateaus often comes down to whether you notice the early signals your body is sending you
In the SURMOUNT-5 trial, which directly compared the two medications, Mounjaro 15 mg produced 20.2% weight loss, while Wegovy 2.4 mg produced 13.7% over 72 weeks
Tirzepatide is the only licenced GLP-1/GIP co-agonist for obesity, with several more GLP-1/GIP co-agonists in development [15]
As demand surges and pipelines swell, the real prize lies beyond weight loss: in diabetes prevention, cardiovascular outcomes, and even neurodegenerative disease